Survey of patient and partner satisfaction following collagenase Clostridium histolyticum treatment for Peyronie's disease.
Andrology 2017 Feb 10. Epub 2017 Feb 10.
Department of Urology, Tulane University School of Medicine, New Orleans, LA, USA.
Intralesional injection of collagenase Clostridium histolyticum (CCH) is a minimally invasive, Food and Drug Administration-approved, effective treatment for Peyronie's disease (PD). To assess the satisfaction of patients and their female sexual partners (FSP) following CCH therapy for PD, we conducted a retrospective review of the records of all patients treated with CCH for PD between 04/2014 and 03/2016. Collected variables included demographics, pre- and post-treatment sexual function, penile curvature, penile vascular findings, and treatment outcomes. Read More